SINGAPORE – Bayer AG may build a new production facility in Singapore to support the ground-breaking cell and gene therapies it is developing to cure Parkinson’s disease.
The German multinational, one of the world’s top pharmaceutical companies, told The Straits Times that it is also looking to partner innovative biotechnology start-ups, including those working on mRNA-based vaccines and therapies.
Please subscribe or log in to continue reading the full article.
Get unlimited access to all stories at $0.99/month
- Latest headlines and exclusive stories
- In-depth analyses and award-winning multimedia content
- Get access to all with our no-contract promotional package at only $0.99/month for the first 3 months*
*Terms and conditions apply.